00:26 , Jan 25, 2019 |  BC Week In Review  |  Financial News

BridgeBio raises $299M to advance rare disease portfolio

BridgeBio Pharma LLC (Palo Alto, Calif.) said it raised $299.2 million on Jan. 23 in a venture round to develop compounds for rare genetic diseases. The company in-licenses preclinical and clinical stage assets from academia...
23:35 , Jan 23, 2019 |  BC Extra  |  Financial News

BridgeBio raises $299M to advance rare disease portfolio

BridgeBio Pharma LLC (Palo Alto, Calif.) said it raised $299.2 million on Wednesday in a venture round to develop compounds for rare genetic diseases. The company in-licenses preclinical and clinical stage assets from academia and...
16:19 , Jun 15, 2018 |  BC Week In Review  |  Company News

Alexion partners with Complement, divests non-core asset

Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) announced a pair of deals on June 11, including a deal with Complement Pharma (Amsterdam, The Netherlands) to develop a preclinical complement 6 (C6) inhibitor for neurodegenerative diseases. The biotech also...
22:51 , Jun 11, 2018 |  BC Extra  |  Company News

Alexion partners with Complement, divests non-core asset

Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) announced a pair of deals on Monday, including a deal with Complement Pharma (Amsterdam, The Netherlands) to develop a preclinical complement 6 (C6) inhibitor for neurodegenerative diseases. The biotech also divested...
17:39 , Apr 20, 2018 |  BioCentury  |  Finance

Refilling Alexion’s cupboard

The first deal by Alexion Pharmaceuticals Inc.’s freshly rebuilt management team serves to amplify its biggest challenge -- it needs many more external assets to break its Soliris eculizumab dependence, and it may not have...
21:27 , Jul 28, 2017 |  BC Week In Review  |  Company News

Alexion announces pipeline restructuring

Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) restructured its pipeline to focus on its core complement inhibitor franchise and its approved rare disease products, dropping early stage rare disease partnerships with Moderna Therapeutics Inc. (Cambridge, Mass.), Blueprint Medicines...
01:21 , Jul 28, 2017 |  BC Extra  |  Company News

Alexion refocusing on complement cascade

Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) restructured its pipeline to focus on its core complement inhibitor franchise and its approved rare disease products, dropping early stage rare disease partnerships with Moderna Therapeutics Inc. (Cambridge, Mass.), Blueprint Medicines...
07:00 , May 18, 2015 |  BioCentury  |  Strategy

Alexion executes

The proposed acquisition of Synageva BioPharma Corp. is Alexion Pharmaceuticals Inc .'s biggest move to date under a four-year-old plan to diversify its portfolio. The plan, announced in 2011, includes expanding Soliris eculizumab beyond paroxysmal...
07:00 , Oct 28, 2013 |  BC Week In Review  |  Clinical News

Cyclic pyranopterin monophosphate regulatory update

Alexion said FDA granted breakthrough therapy designation for ALXN1101 to treat molybdenum cofactor deficiency (MoCD) Type A, a rare genetic disorder characterized by severe brain damage and rapid death in newborns. Alexion is conducting a...
07:00 , Oct 28, 2013 |  BioCentury  |  Finance

Highlights of weekly biotech stock moves

Regulatory milestones Actelion Ltd. (SIX:ATLN) was off CHF0.20 to CHF69.15 on Friday after EMA's CHMP backed approval of Opsumit macitentan for pulmonary arterial hypertension (PAH). Actelion gained CHF4.55 on the week. The move included a...